v2.3.0.11
Acquisition of King Pharmaceuticals Inc - Included In Consolidated Statements of Income (Detail) (USD $)
In Millions
 3 Months Ended 6 Months Ended
Jul. 03, 2011
Jul. 04, 2010
Jul. 03, 2011
Jul. 04, 2010
Business Acquisition [Line Items]        
Purchase accounting adjustment for estimated sales of acquisition-date inventory at fair value $ 3,805 [1] $ 3,684 [1] $ 7,498 [1] $ 7,886 [1]
Purchase accounting adjustment for restructuring and integration costs 479 [2] 885 [2] 1,373 [2] 1,591 [2]
King [Member]
        
Business Acquisition [Line Items]        
Revenues 357   581  
Loss from continuing operations attributable to Pfizer Inc. common shareholders (5) [3]   (74) [3]  
King [Member] | Business Combination Effect on Consolidated Results [Member]
        
Business Acquisition [Line Items]        
Purchase accounting adjustment for estimated sales of acquisition-date inventory at fair value 61   (119)  
Purchase accounting adjustment for amortization of identifiable intangible assets acquired 43   71  
Purchase accounting adjustment for restructuring and integration costs $ 63   $ 159  
[1] Exclusive of amortization of intangible assets, except as disclosed in Note 11B. Goodwill and Other Intangible Assets: Other Intangible Assets.
[2] From the beginning of our cost-reduction and transformation initiatives in 2005 through July 3, 2011, Employee termination costs represent the expected reduction of the workforce by approximately 55,400 employees, mainly in manufacturing and sales and research, of which approximately 39,100 employees have been terminated as of July 3, 2011. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. Asset impairments primarily include charges to write down property, plant and equipment to fair value. Other primarily includes costs to exit certain assets and activities. These restructuring charges in 2011 are associated with the following: ● For the three months ended July 3, 2011, Primary Care operating segment ($87 million), Specialty Care and Oncology operating segment ($7 million), Established Products and Emerging Markets operating segment ($12 million), Animal Health and Consumer Healthcare operating segment ($4 million), research and development operations ($51 million), manufacturing operations ($81 million) and Corporate ($23 million). ● For the six months ended July 3, 2011, Primary Care operating segment ($133 million), Specialty Care and Oncology operating segment ($42 million), Established Products and Emerging Markets operating segment ($15 million), Animal Health and Consumer Healthcare operating segment ($14 million), Nutrition operating segment ($2 million), research and development operations ($473 million), manufacturing operations ($156 million) and Corporate ($135 million).
[3] Includes purchase accounting adjustments related to the fair value adjustments for acquisition-date inventory estimated to have been sold ($61 million pre-tax in the second quarter of 2011 and $119 million pre-tax in the first six months of 2011), amortization of identifiable intangible assets acquired from King ($43 million pre-tax in the second quarter of 2011 and $71 million pre-tax in the first six months of 2011) and restructuring and integration costs ($63 million pre-tax in the second quarter of 2011 and $159 million pre-tax in the first six months of 2011).